Evidence for a graft-versus-tumor effect in a patient treated with marrow ablative chemotherapy and allogeneic bone marrow transplantation for breast cancer
Evidence for a graft-versus-tumor effect in a patient treated with marrow ablative chemotherapy and allogeneic bone marrow transplantation for breast cancer
复制标题
DOI：
10.1182/blood.v88.4.1501.bloodjournal8841501
复制
发表时间：
1996-08-15
期刊：
影响因子：
20.3
通讯作者：
Niederwieser, D
中科院分区：
文献类型：
--
作者：
Eibl, B;Schwaighofer, H;Niederwieser, D
移植物抗白血病（GvL）已被证明是血液系统恶性肿瘤中重要的免疫介导的抗肿瘤作用。目前尚不清楚这种免疫介导的抗肿瘤作用是否对实体瘤患者具有临床意义，一名患有炎性乳腺癌的 32 岁女性接受了她 HLA 相同的兄弟姐妹的骨髓移植 (BMT)。在移植物抗宿主病 (GvHD) 期间，培养细胞毒性 T 淋巴细胞，并通过针对患者和供体的 B 和 T 淋巴细胞以及一组乳腺癌细胞系的铬释放测定进行测试，在移植后的最初几周内，与临床 GvHD 同时观察到肝转移的消退。此外，从患者的血液中分离出识别乳腺癌靶细胞的镜像组织相容性抗原（MiHA）特异性和主要组织相容性复合体（MHC）I类抗原限制性细胞毒性T淋巴细胞。用肿瘤坏死因子(TNF)-α而不是干扰素(IFN)-α或IFN-γ预处理这些靶细胞会增加这些细胞对细胞毒性T淋巴细胞裂解的易感性。临床过程和体外结果表明，乳腺癌同种异体骨髓移植后可能存在移植物抗肿瘤（GvT）效应，但需要更大规模的临床经验来确定GvT效应对实体瘤患者的临床疗效。 (C) 1996 年，美国血液学会。
Graft-versus-leukemia (GvL) has been shown to be an important immune-mediated antitumor effect in hematologic malignancies. It is still unknown whether such an immune-mediated antitumor effect has clinical implications in patients with solid tumors, A 32-year-old woman with inflammatory breast cancer received a bone marrow transplant (BMT) from her HLA-identical sibling. During graft-versus-host disease (GvHD) cytotoxic T lymphocytes were grown and tested in a chromium-release assay against B and T lymphocytes of the patient and donor and against a panel of breast cancer cell lines, Resolution of liver metastases was observed simultaneously with clinical GvHD in the first weeks after transplant. In addition, mirror histocompatibility antigen (MiHA)-specific and major histocompatibility complex (MHC) class I antigen-restricted cytotoxic T lymphocytes recognizing breast carcinoma target cells were isolated from the blood of the patient. Pretreatment of such target cells with tumor necrosis factor (TNF)-alpha but not with interferon (IFN)-alpha or IFN-gamma increased susceptibility of these cells to lysis by cytotoxic T lymphocytes. Clinical course and in vitro results suggest that a graft-versus-tumor (GvT) effect might exist after allogeneic BMT for breast cancer, However, clinical experience on a larger scale would be required to determine the clinical efficacy of GvT effects in patients with solid tumors. (C) 1996 by The American Society of Hematology.